There are several factors physicians consider when predicting the likelihood of complications including hydrops in prenatal cases of SCT. Factors considered might include:

• Tumor size
• Tumor composition (whether the tissue is solid, fluid-filled, or both)
• Rate of tumor growth
• Degree of vascularization (blood flow to the tumor)
• Signs of impaired cardiac function (including hydrops)
• Development and timing of polyhydramnios (too much amniotic fluid)

Many of these factors need to be followed over time with routine ultrasound, MRI, and echocardiogram. Given the complicated nature of the development of SCT and the multiple factors involved in determining prognosis, we cannot predict the likelihood of hydrops.

We would encourage you to discuss the potential for a referral to a high risk maternal fetal medicine specialist or a fetal treatment center with your OBGYN to address your concerns and provide follow up care.

The treatment for sacrococcygeal teratoma (SCT) typically involves surgery to remove the tumor. Surgery occurs either in the prenatal period or shortly after delivery. The timing is dependent on the size of the tumor and the associated symptoms.